Acorda's MS Drug Amaya Panel Review Leaves Little Time To React
This article was originally published in The Pink Sheet Daily
The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.
You may also be interested in...
Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.
A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.
Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.